0
Skip to Content
B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
Folder: ABOUT
Back
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
Folder: GET INVOLVED
Back
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
Folder: RESEARCH
Back
RESEARCH
OVERVIEW
RESEARCH GRANTS
Folder: NEED HELP?
Back
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
Uncovering the role of chromosome 21 in Down syndrome-associated leukemias
Northeast, Connecticut Julia Travagline 11/20/24 Northeast, Connecticut Julia Travagline 11/20/24

Uncovering the role of chromosome 21 in Down syndrome-associated leukemias

Uncovering the role of chromosome 21 in Down syndrome-associated leukemias

Dr. Jason Sheltzer, Ph.D. – Yale University, New Haven, CT

Read More
Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma

Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma

Dr. Jamie Anastas, Ph.D. – Baylor College of Medicine, Houston, TX

Read More
The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia
New York, Northeast Julia Travagline 11/20/24 New York, Northeast Julia Travagline 11/20/24

The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia

The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia

Dr. lannis Aifantis, Ph.D. – New York University Grossman School of Medicine, New York, NY

Read More
CAR gamma delta T cell-based multi-pronged immunotherapy for AML
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

CAR gamma delta T cell-based multi-pronged immunotherapy for AML

CAR gamma delta T cell-based multi-pronged immunotherapy for AML

Dr. Norihiro Watanabe, Ph.D. – Baylor College of Medicine

Read More
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Midwest, Michigan Julia Travagline 11/20/24 Midwest, Michigan Julia Travagline 11/20/24

Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT

Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT

Dr. John Prensner, M.D., Ph.D. – University of Michigan Medical Center (Michigan Medicine), Ann Arbor, MI

Read More
Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis
Northeast, Washington D.C. Julia Travagline 11/20/24 Northeast, Washington D.C. Julia Travagline 11/20/24

Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis

Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis

Dr. Yanxin Pei, M.D. – Children's Research Institute (CNMC), Washington, D.C.

Read More
Validating PRL2 as a New Therapeutic Target in T-ALL
Midwest, Illinois Julia Travagline 11/20/24 Midwest, Illinois Julia Travagline 11/20/24

Validating PRL2 as a New Therapeutic Target in T-ALL

Validating PRL2 as a New Therapeutic Target in T-ALL

Dr. Loretta Li, M.D. – Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

Read More
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
International, Israel Julia Travagline 11/20/24 International, Israel Julia Travagline 11/20/24

Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma

Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma

Dr. Liron Grossmann, M.D. – The Sheba Fund for Health Service and Research, Israel

Read More
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
Northeast, New York Julia Travagline 11/20/24 Northeast, New York Julia Travagline 11/20/24

The Role of S100A8/A9-IL6R in B-ALL Chemoresistance

The Role of S100A8/A9-IL6R in B-ALL Chemoresistance

Dr. William Carroll, M.D. – New York University Grossman School of Medicine, New York, NY

Read More

HELPFUL LINKS

BLOG

RESEARCH

SCHOOLS

COMPANIES

FACTS

PRIVACY

ABOUT

B+ EVENTS

B+ HEROES

HERO FUNDS

B+ GEAR

GET ASSISTANCE

 

CONNECT WITH US

Address: The B+ Foundation
101 Rockland Circle
Wilmington, DE 19803

Phone: 302.563.8389 | 845.304.6347
Email: Joe@BePositive.org | Carly@BePositive.org

Family Assistance: Katie@BePositive.org | 609.330.6775

 
Today-logo.png
 
ICRP-logo copy.jpg
 

CONTACT US

Name *
Thank you!

 The Andrew McDonough B+ Foundation is an IRS-certified 501(c)3 organization. Our Tax ID # is 42-1741037.

B+® is a registered trademark